To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Supriya Sharma · Chief Medical Advisor, Health Canada (HC)
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Rodrigo Arancibia · Sr. Director for Innovation, Science and Economic Development Canada, Innovation, Science and Economic Development Canada (ISED)
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Sandenga Yeba · Deputy Chief of Staff and Director of Policy, Minister of Health's Office, House of Commons
Bryn Savage · Policy Advisor, Minister of Health's Office, House of Commons
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Patricia Conrod · Scientific Director of the CIHR Institute of Neurosciences, Mental Health and Addiction, Canadian Institutes of Health Research (CIHR)
Jane Rylett · Scientific Director of the CIHR Institute of Aging, Canadian Institutes of Health Research (CIHR)
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Bryn Savage · Policy advisor, Minister of Health's office, House of Commons
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Kiren Dar · Constituency Assistant, House of Commons
Shelley Kulperger · Office Manager, House of Commons
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.Read more
Policies or programs related to access to care and potential treatments for the ALS Community.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.